Chemomab Therapeutics (CMMB) AI Stock Analysis

• Market Cap: $10.03M
• Dividend Yield: N/A
• Average Volume (3M): 207.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: N/A
• EPS Growth: 53.19%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 6,155,117
• 10 Day Avg. Volume: 363,095
• 30 Day Avg. Volume: 207,955
• PEG Ratio: 0.04
• Price to Book (P/B): 2.40
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.10
• Enterprise Value/Market Cap: 0.18
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -52.43
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: $17.50
• Price Target Upside: 973.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: $1.50 ▼(-7.98% Downside)

The score is driven primarily by weak financial performance (no revenue, ongoing losses and cash burn with shrinking equity) and very bearish technical conditions (below all major moving averages with negative MACD). Valuation provides little support due to negative earnings and no dividend yield data.

Positive Factors

Strong Equity Base

A strong equity base indicates financial stability and low leverage, providing a solid foundation for future growth and resilience against financial volatility.

Innovative Product Pipeline

CM-101's focus on fibrosis and inflammation represents a significant opportunity in unmet medical needs, potentially leading to breakthrough treatments and strong market demand.

Strategic Partnerships

Strategic partnerships provide financial support for R&D, enabling progress in drug development and potential revenue streams from licensing and milestone payments.

Negative Factors

Zero Revenue

The absence of revenue highlights the company's reliance on external funding, posing a risk to sustainability and necessitating successful product commercialization.

Negative Cash Flow

Persistent negative cash flow without revenue generation can strain financial resources, requiring ongoing external financing and impacting long-term viability.

Ongoing Losses

Sustained losses reflect operational challenges and high costs, emphasizing the critical need for successful product development and market entry to achieve profitability.

Chemomab Therapeutics Business Overview & Revenue Model

Company Description

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

How the Company Makes Money

Chemomab Therapeutics generates revenue primarily through strategic partnerships, collaborations, and potentially from licensing agreements related to its proprietary technologies and drug candidates. As a clinical-stage company, it may also receive milestone payments, research funding, and royalties from partnerships with larger pharmaceutical companies. These collaborations can provide financial support for ongoing research and development activities, helping the company advance its pipeline towards commercialization. Currently, the company does not generate revenue from product sales as its drug candidates are still undergoing clinical trials.

Chemomab Therapeutics Financial Statement Overview

Summary

Financials are high-risk: no revenue across reported years, continued sizable operating/net losses, and persistently negative free cash flow. Positives include improving losses and cash burn in 2024 versus 2023 and low leverage, but declining equity indicates ongoing balance-sheet depletion.

Income Statement

The company has generated no revenue across the reported annual periods, while operating losses remain significant (EBIT of about -$14.7M in 2024 vs. -$25.5M in 2023), indicating a business still in heavy R&D/investment mode. Net losses improved in 2024 (about -$13.9M) versus 2022–2023, which is a positive trajectory, but profitability remains deeply negative and there is no visible path to margins without revenue.

Balance Sheet

Leverage is very low, with total debt modest and debt-to-equity consistently small (roughly ~0.02 in 2023–2024), which reduces financial distress risk. However, equity has declined materially over time (about $61.5M in 2021 down to ~$13.5M in 2024), reflecting ongoing losses and balance sheet depletion; returns on equity are strongly negative, underscoring continued value erosion.

Cash Flow

Cash generation is weak with persistently negative operating and free cash flow (free cash flow around -$15.5M in 2024 and -$23.6M in 2023). The burn rate improved meaningfully in 2024 versus 2023, but free cash flow still closely tracks net losses (near 1:1), suggesting limited non-cash offsets and continued reliance on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-33.69K	-53.25K	-66.83K	-57.77K	-34.02K	-80.00K
EBITDA	-10.59M	-13.96M	-25.39M	-28.48M	-12.33M	-5.95M
Net Income	-10.09M	-13.95M	-24.22M	-27.65M	-12.48M	-5.95M
Balance Sheet
Total Assets	12.37M	16.96M	22.15M	43.06M	64.35M	12.48M
Cash, Cash Equivalents and Short-Term Investments	10.06M	14.27M	19.78M	39.89M	61.16M	11.70M
Total Debt	0.00	324.00K	392.00K	214.00K	343.00K	607.00K
Total Liabilities	1.14M	3.43M	5.15M	6.84M	2.89M	1.67M
Stockholders Equity	11.23M	13.54M	17.00M	36.22M	61.47M	10.80M
Cash Flow
Free Cash Flow	0.00	-15.46M	-23.55M	-20.36M	-12.62M	-12.84M
Operating Cash Flow	0.00	-15.46M	-23.55M	-20.29M	-12.38M	-12.80M
Investing Cash Flow	0.00	2.31M	15.84M	19.46M	-45.22M	102.72K
Financing Cash Flow	0.00	9.91M	3.49M	-804.84K	61.12M	299.08K

Chemomab Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMMB, the sentiment is Negative. The current price of 1.63 is below the 20-day moving average (MA) of 1.70, below the 50-day MA of 1.99, and below the 200-day MA of 3.48, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 41.25 is Neutral, neither overbought nor oversold. The STOCH value of 36.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CMMB.

Chemomab Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QTTB	51 Neutral	$49.46M	-1.12	―	―	―	49.57%
PASG	49 Neutral	$32.98M	-0.63	-87.18%	―	―	38.42%
TENX	48 Neutral	$81.98M	―	-44.80%	―	―	92.89%
CALC	40 Underperform	$9.51M	-0.38	-526.36%	―	―	-2.46%
LGVN	40 Underperform	$11.52M	-0.38	-119.92%	―	-22.41%	78.88%
CMMB	39 Underperform	$10.03M	-0.78	-73.63%	―	―	53.19%

Chemomab Therapeutics Corporate Events

Chemomab Therapeutics Advances Nebokitug Phase 3 Trial with Regulatory Support

Chemomab Therapeutics announced its third quarter 2025 financial results and provided a corporate update, highlighting significant progress in its nebokitug Phase 3 trial for primary sclerosing cholangitis (PSC). The company received positive feedback from both the FDA and EMA, supporting a single Phase 3 registration trial with a composite endpoint, and presented favorable Phase 2 data at the AASLD 2025 conference. Chemomab is exploring multiple partnering options to support the Phase 3 program and expects its cash runway to last through the end of 2026.

The most recent analyst rating on (CMMB) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.